CCT2 and early-onset autosomal dominant Alzheimer disease: The selective degradation of solid protein aggregates by CCT2 has important implications for the treatment of diseases characterized by the accumulation of insoluble protein deposits, such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease (Erkkinen et al., 2018; Fernández-Ruiz et al., 2015; Sujkowski et al., 2022).